• 1
    Jemal A,Murray T,Samuels A,Ghafoor A,Ward E,Thun MJ. Cancer statistics, 2003. CA Cancer J Clin. 2003; 53: 5-26.
  • 2
    Sasson AR,Sigurdson ER. Surgical treatment of liver metastases. Semin Oncol. 2002; 29: 107-118.
  • 3
    Bengtsson G,Carlsson G,Hafstrom L,Jonsson PE. Natural history of patients with untreated liver metastases from colorectal cancer. Am J Surg. 1981; 141: 586-589.
  • 4
    Wagner JS,Adson MA,Van Heerden JA,Adson MH,Ilstrup DM. The natural history of hepatic metastases from colorectal cancer. A comparison with resective treatment. Ann Surg. 1984; 199: 502-508.
  • 5
    Tomlinson JS,Jarnagin WR,DeMatteo RP, et al. Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol. 2007; 25: 4575-4580.
  • 6
    Bentrem DJ,Dematteo RP,Blumgart LH. Surgical therapy for metastatic disease to the liver. Annu Rev Med. 2005; 56: 139-156.
  • 7
    Adam R,Aloia T,Levi F, et al. Hepatic resection after rescue cetuximab treatment for colorectal liver metastases previously refractory to conventional systemic therapy. J Clin Oncol. 2007; 25: 4593-4602.
  • 8
    Goldberg RM,Rothenberg ML,Van Cutsem E, et al. The continuum of care: a paradigm for the management of metastatic colorectal cancer. Oncologist. 2007; 12: 38-50.
  • 9
    Dancey JE,Shepherd FA,Paul K, et al. Treatment of nonresectable hepatocellular carcinoma with intrahepatic 90Y-microspheres. J Nucl Med. 2000; 41: 1673-1681.
  • 10
    Russell JLJr,Carden JL,Herron HL. Dosimetry calculations for yttrium-90 used in the treatment of liver cancer. Endocurietherapy/Hyperthermia Oncol. 1988; 4: 171-186.
  • 11
    Snyder W,Ford M,Warner G,Watson S. ‘S’ Absorbed Dose per Unit Cumulated Activity for Selected Radionuclides and Organs. New York, NY: Society of Nuclear Medicine; 1975.
  • 12
    Salem R,Thurston KG. Radioembolization with 90yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies: part 1: technical and methodologic considerations. J Vasc Interv Radiol. 2006; 17: 1251-1278.
  • 13
    Ho S,Lau WY,Leung TW,Chan M,Johnson PJ,Li AK. Clinical evaluation of the partition model for estimating radiation doses from yttrium-90 microspheres in the treatment of hepatic cancer. Eur J Nucl Med. 1997; 24: 293-298.
  • 14
    Lau WY,Ho S,Leung TW, et al. Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90yttrium microspheres. Int J Radiat Oncol Biol Phys. 1998; 40: 583-592.
  • 15
    Kaplan EL,Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457-481.
  • 16
    Chau I,Chan S,Cunningham D. Overview of preoperative and postoperative therapy for colorectal cancer: the European and United States perspectives. Clin Colorectal Cancer. 2003; 3: 19-33.
  • 17
    Coutinho AK,Rocha Lima CM. Metastatic colorectal cancer: systemic treatment in the new millennium. Cancer Control. 2003; 10: 224-238.
  • 18
    O'Neil BH,Goldberg RM. Novel chemotherapeutic and targeted agents in metastatic colorectal cancer: the time has arrived. Expert Opin Investig Drugs. 2003; 12: 1939-1949.
  • 19
    Kennedy AS,Coldwell D,Nutting C, et al. Resin 90Y-microsphere brachytherapy for unresectable colorectal liver metastases: modern USA experience. Int J Radiat Oncol Biol Phys. 2006; 65: 412-425.
  • 20
    Lewandowski RJ,Thurston KG,Goin JE, et al. 90Y microsphere (TheraSphere) treatment for unresectable colorectal cancer metastases of the liver: response to treatment at targeted doses of 135-150 Gy as measured by [18F]fluorodeoxyglucose positron emission tomography and computed tomographic imaging. J Vasc Interv Radiol. 2005; 16: 1641-1651.
  • 21
    Sharma RA,Van Hazel GA,Morgan B, et al. Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy. J Clin Oncol. 2007; 25: 1099-1106.
  • 22
    Lewandowski RJ,Sato KT,Atassi B, et al. Radioembolization with y microspheres: angiographic and technical considerations. Cardiovasc Interv Radiol. 2007; 30: 571-592.
  • 23
    Liu DM,Salem R,Bui JT, et al. Angiographic considerations in patients undergoing liver-directed therapy. J Vasc Interv Radiol. 2005; 16: 911-935.
  • 24
    Salem R,Lewandowski RJ,Sato KT, et al. Technical aspects of radioembolization with 90Y microspheres. Tech Vasc Interv Radiol. 2007; 10: 12-29.
  • 25
    Salem R. Radioembolization with 90Y microspheres: technical considerations. J Vasc Interv Radiol. 2007; 18: 1460-1461.
  • 26
    Van Cutsem E,Peeters M,Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol. 2007; 25: 1658-1664.
  • 27
    Cunningham D,Humblet Y,Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004; 351: 337-345.
  • 28
    Lenz HJ,Van Cutsem E,Khambata-Ford S, et al. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol. 2006; 24: 4914-4921.
  • 29
    Gallagher DJ,Capanu M,Raggio G,Kemeny N. Hepatic arterial infusion plus systemic irinotecan in patients with unresectable hepatic metastases from colorectal cancer previously treated with systemic oxaliplatin: a retrospective analysis. Ann Oncol. 2007; 18: 1995-1999.
  • 30
    Wong CY,Qing F,Savin M, et al. Reduction of metastatic load to liver after intraarterial hepatic yttrium-90 radioembolization as evaluated by [18F]fluorodeoxyglucose positron emission tomographic imaging. J Vasc Interv Radiol. 2005; 16: 1101-1106.
  • 31
    Wong CY,Salem R,Qing F, et al. Metabolic response after intraarterial 90Y-glass microsphere treatment for colorectal liver metastases: comparison of quantitative and visual analyses by 18F-FDG PET. J Nucl Med. 2004; 45: 1892-1897.
  • 32
    Wong CY,Salem R,Raman S,Gates VL,Dworkin HJ. Evaluating 90Y-glass microsphere treatment response of unresectable colorectal liver metastases by [18F]FDG PET: a comparison with CT or MRI. Eur J Nucl Med Mol Imaging. 2002; 29: 815-820.
  • 33
    Koopman M,Antonini NF,Douma J, et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet. 2007; 370: 135-142.
  • 34
    Seymour MT,Maughan TS,Ledermann JA, et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet. 2007; 370: 143-152.
  • 35
    Adam R,Avisar E,Ariche A, et al. Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal. Ann Surg Oncol. 2001; 8: 347-353.
  • 36
    Adson MA,van Heerden JA,Adson MH,Wagner JS,Ilstrup DM. Resection of hepatic metastases from colorectal cancer. Arch Surg. 1984; 119: 647-651.
  • 37
    Siperstein AE,Berber E,Ballem N,Parikh RT. Survival after radiofrequency ablation of colorectal liver metastases: 10-year experience. Ann Surg. 2007; 246: 559-565; discussion 565-567.